Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
ovarian cancer treatment
market6 mentionslast seen Nov 13, 2026
A cancer application domain targeted by the theranostic ferrite nanoparticles studied in the document.
Relationships 6
- stenoparibapplies toovarian cancer treatment99% confidence2 sources
- ferrite nanoparticleapplies toovarian cancer treatment95% confidence1 source
- ARR-002applies toovarian cancer treatment95% confidence1 source
- APR-1051applies toovarian cancer treatment90% confidence1 source
- Zn0.35Mn0.25Fe2.4O4applies toovarian cancer treatment90% confidence1 source
- INCB123667applies toovarian cancer treatment88% confidence1 source
Relationship
stenoparibapplies toovarian cancer treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 6, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Allarity has advanced its Phase 2 ovarian cancer program
- filingSEC EDGARSep 29, 2026Allarity Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer